September 2024 Tender Notification
Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2023/24 Invitation to Tender dated 31 October 2023.
Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on the 12th of October 2024 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.
- 30 September 2024 Tender Notification [PDF 196 KB]
2023/24 Tender – Principal Supply Status applies until 30 June 2027
Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule
The decisions were as follows:
- Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|
|
Clomipramine hydrochloride |
Tab 25 mg; 50 tablet blister pack |
$11.99 (per 30 tab) |
$16.99 |
APO Clomipramine (Arrotex) |
1 February 2025 |
1 July 2025 |
Clomipramine Teva (Teva); Anafranil (Teva) |
|
Diclofenac sodium |
Eye drops 0.1 %, single dose; 10 plastic ampoule pack |
$8.80 (per 5 ml OP) |
$1.85 |
Diclofenac Devatis (Devatis) |
1 February 2025 |
1 July 2025 |
Voltaren Ophtha (Novartis)1,2 |
|
Diclofenac sodium |
Eye drops 0.1 %, single dose; 30 plastic ampoule pack |
$8.80 (per 5 ml OP) |
$5.54 |
Diclofenac Devatis (Devatis) |
1 February 2025 |
1 July 2025 |
Voltaren Ophtha (Novartis)1,2 |
|
1Novartis’ brand of diclofenac sodium eye drops 0.1%; per 5 ml OP Voltaren Ophtha (Pharmacode 781851) to be delisted 1 December 2024. 2Novartis’ brand of nepafenac eye drops 0.3%; per 3 ml OP Ilevro (Pharmacode 2655969) to be delisted 1 July 2025. |
|||||||
Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.
- Tenders awarded to pharmaceuticals where at least one other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Clomipramine hydrochloride |
Tab 25 mg; 50 tablet blister pack |
$11.99 (per 30 tab) |
$16.99 |
APO Clomipramine (Arrotex) |
5% |
1 February 2025 |
1 July 2025 |
Clomipramine Teva (Teva) |
|
Diclofenac sodium |
Eye drops 0.1 %, single dose; 10 plastic ampoule pack |
$8.80 (Per 5 ml) |
$1.85 |
Diclofenac Devatis (Devatis) |
5% |
1 February 2025 |
1 July 2025 |
Voltaren Ophtha (Novartis)1,3 |
|
Diclofenac sodium |
Eye drops 0.1 %, single dose; 30 plastic ampoule pack |
$8.80 (Per 5 ml) |
$5.54 |
Diclofenac Devatis (Devatis) |
5% |
1 February 2025 |
1 July 2025 |
Voltaren Ophtha (Novartis)1,3 |
|
1Novartis’ brand of diclofenac sodium eye drops 0.1%; per 5 ml OP Voltaren Ophtha (Pharmacode 781851) to be delisted 1 December 2024. 3Nepafenac eye drops 0.3% to be delisted 1 July 2025. |
||||||||
Tender declines – Products where no tender is to be awarded for Principal Supply Status
Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2023/24 Invitation to Tender, dated 31 October 2023.
|
Chemical Name |
Line Item |
|---|---|
|
Amphotericin B |
Liposomal inj 50 mg |
|
Clomipramine hydrochloride |
Tab 10 mg |
|
Fluticasone propionate |
Metered aqueous nasal spray, 50 mcg per dose |
|
Glibenclamide |
Tab 5 mg |
|
Mifepristone |
Tab 200 mg |
|
Neostigmine metisulfate with glycopyrronium bromide |
Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml |
|
Rasagiline |
Tab 1 mg |
|
Tadalafil |
Tab/cap 5 mg |
|
Tadalafil |
Tab/cap 10 mg |
|
Tadalafil |
Tab/cap 20 mg |
|
Verapamil hydrochloride |
Inj 2.5 mg per ml, 2 ml |
For products included in the 2022/23 and 2023/24 Invitation to Tender where no announcement has yet been made, a decision is still pending subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.